North America Adenomyosis Drugs Market, By Type (Diffuse, Nodular, Sclerotic, Adult Cystic, Others), Treatment (Hormone Medications, Anti-Inflammatory Drugs), Patient Type (AdultGeriatric, Adolescence), Dosage Form (Parenteral, Oral, Others), End User (Hospitals, Clinics, Specialty Centers, Ambulatory Centers, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) - Industry Trends and Forecast to 2029.
Market Analysis and Insights
Adenomyosis is a benign uterine disorder in which endometrial glands and stroma are pathologically demonstrated in the myometrium. Women affected by adenomyosis may present with abnormal uterine bleeding (AUB), dysmenorrhea, dyspareunia, or infertility, but one-third of them are asymptomatic. Over the years, adenomyosis has remained a histopathological diagnosis made after hysterectomy in perimenopausal women with heavy menstrual bleeding (HMB) or pelvic pain. However, adenomyosis has also become a condition identified in young fertile-age women over the last decade because of the recent advancements in imaging techniques, even though a shared definition and classification are still lacking. Despite the improvement of diagnostic tools, the awareness of the condition is still poor.
The drugs used for the treatment of adenomyosis generally include anti-inflammatory drugs and hormonal drugs such as gonadotropin-releasing hormone analogs (Gnrh Analogs), estrogen-progestin, selective progesterone receptor modulators (SPRMs) or progestin, aromatase inhibitors, and gonadotropin-releasing hormone antagonist, among others. Some of these drugs are used to reduce adenomyotic lesion size and improve the patient's dysmenorrhea and quality of life.
The demand for adenomyosis drugs has increased more in developed countries. These countries had reimbursement policies for treatment along with the high prevalence of the disease and increasing healthcare expenditure. The market will grow in the forecasted period due to the exploration of emerging markets and increasing support of private and government agencies for treatment.
North America adenomyosis drugs market report provides details of market share, new developments, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue impact solution to achieve your desired goal. Strategic initiatives such as collaboration, agreement, and signing of sales agreements to invent and innovate pharmacological treatments are the major drivers which propelled the demand of the market in the forecast period.
North America adenomyosis drugs market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that the North America adenomyosis drugs market will grow at a CAGR of 6.4% during the forecast period of 2022 to 2029.
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2019 - 2014) |
|
Quantitative Units |
Revenue in USD Thousand, Pricing in USD |
|
Segments Covered |
By Type (Diffuse, Nodular, Sclerotic, Adult Cystic, Others), Treatment (Hormone Medications, Anti-Inflammatory Drugs), Patient Type (Adult, Geriatric, Adolescence), Dosage Form (Parenteral, Oral, Others), End User (Hospitals, Clinics, Specialty Centers, Ambulatory Centers, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) |
|
Countries Covered |
U.S., Canada, and Mexico |
|
Market Players Covered |
Mayne Pharma Group Limited, Accord Healthcare, Tolmar Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, TerSera Therapeutics LLC, Ferring B.V., Lannett, Par Pharmaceutical (A Subsidiary of Endo International plc), Hikma Pharmaceuticals PLC, Context Therapeutics Inc., Viatris Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Zydus Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd, AbbVie Inc., Abbott, GlaxoSmithKline plc., Novartis AG, Amneal Pharmaceuticals LLC, Johnson & Johnson Services, Inc., Sanofi, Dr. Reddy's Laboratories Ltd., among others |
Market Definition
Adenomyosis represents a unique pathophysiological condition in which normal-appearing endometrial mucosa resides within the myometrium and is thus protected from menstrual shedding. The resulting ectopic presence of endometrial tissue composed of glands and stroma is thought to affect normal contractile function and peristalsis of uterine smooth muscle, causing menometrorrhagia, infertility, and adverse obstetric outcomes. Adenomyosis imposes a substantial socioeconomic burden from increased medical care and loss of work productivity without mentioning the compromised quality of life.
Adenomyosis has a negative impact on women's quality of life in a high percentage of cases because of abnormal uterine bleeding and pain requiring a lifelong management plan through medical or surgical treatment. The choice depends on the woman's age, reproductive status, and clinical symptoms. However, the disease is increasingly diagnosed in young women with reproductive desire, and conservative treatments are preferred, such as hormonal medications.
North America Adenomyosis Drugs Market Dynamics
Drivers
- High prevalence of adenomyosis disorders
Gynecologic disorders affect the female reproductive system. The most common symptoms of gynecologic disorders include pelvic pain, endometriosis, adenomyosis, abnormal vaginal bleeding, and breast pain and lumps, among others. The significance and severity of these symptoms often depend on age, as these symptoms may be related to hormonal changes that occur with aging.
With the increasing women population worldwide, the target population for female reproductive disorder has also increased. Adenomyosis, a gynecologic condition characterized by the presence of endometrial glands and stroma within the myometrium, can significantly reduce the lifestyle of an individual. Adenomyosis occurs in 8.8% to 61.5% of women undergoing hysterectomy, and rates vary widely by differences in diagnostic criteria and variations between and within pathologists. The prevalence is estimated to range from 20% to 34%, based on patients referred for pelvic imaging rather than the general population of women.
- Advancement in the diagnosis of adenomyosis
The development of imaging techniques, such as MRI and transvaginal ultrasonography (TVUS), has allowed clinicians to make a non-invasive diagnosis of adenomyosis in women also undergoing conservative treatments, identifying different phenotypes of the disease. After some attempts of histological classification, adenomyosis is classified into four subtypes according to MRI lesion localization in the inner or outer myometrium: intrinsic, extrinsic, intramural, and indeterminate.
Opportunity
- Increase demand for disease-specific drug treatment
According to pathogenic mechanisms, several medical hormonal and non-hormonal treatments are used off-label to manage pain and bleeding and to improve fertility outcomes. The use of GnRHa is indicated before fertility treatments to improve the chances of pregnancy in infertile women with adenomyosis, and the highest pregnancy rate is reported in those undergoing frozen embryo transfer after GnRHa pre-treatment. In contrast, the use of GnRHa for pain and bleeding should be considered only for short-term treatment because of menopausal effects. The levonorgestrel-releasing intrauterine system (LNG-IUS) is also an effective, reversible, and long-term treatment used successfully to treat adenomyosis. Results show that it reduces menstrual bleeding, pain, and uterine volume and has an overall satisfaction of 72%. However, new drugs, such as selective progesterone receptor modulators, aromatase inhibitors, valproic acid, and anti-platelet therapy, are under development for the treatment of adenomyosis.
Restraints/Challenges
The diagnostic tests for adenomyosis include highly technologically advanced products. The development of those products involves rigorous research and development by the developing player. Thus, the cost of the product remains high, which proportionally increases the cost of testing. The diagnostic tools and techniques used for the diagnosis of adenomyosis include ovarian endometrioma, adhesions, and deep nodular forms of the disease that often require ultrasonography or magnetic resonance imaging (MRI) to detect. Histologic verification, usually following surgical/laparoscopic visualization, can be useful in confirming the diagnosis, particularly for the most common superficial lesions.
The therapy of adenomyosis involves different stages and different procedures of treatment. Adenomyosis may be treated with surgery, hormonal drugs, anti-inflammatory drugs, etc. The diagnosis of adenomyosis is difficult, and this subsequently results in difficulty in the management of these patients, especially those who are asymptomatic but have a strong desire to preserve their uterus. Herbal drugs and home remedies are used as alternative therapies for the treatment of adenomyosis.
Recent Developments
- In October 2021, Debiopharm, a Swiss-based, Asia-Pacific biopharmaceutical company, and Dexa Medica, a leading Indonesian pharmaceutical company, announced the Indonesian launch of triptorelin for the treatment of women with gynecological disorders, particularly adenomyosis, and its related diseases
- In September 2019, Professor Caroline Gargett and collaborators at the University of Queensland and Monash IVF were awarded a three-year USD 2.07 Million (AUD 3.05 Million) grant to determine the cause of adenomyosis and the physiological processes associated with the diseases
North America Adenomyosis Drugs Market Divide
North America adenomyosis drugs market is categorized into six notable segments which are based on type, treatment, patient type, dosage form, distribution channel, and end user . The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Diffuse
- Nodular
- Sclerotic
- Adult cystic
- Others
On the basis of type, the North America adenomyosis drugs market is segmented into diffuse, nodular, sclerotic, adult cystic, and others.
Treatment
- Hormone medications
- Anti-inflammatory drugs
- Others
On the basis of treatment, the North America adenomyosis drugs market is segmented into hormone medications, anti-inflammatory drugs, and others.
Patient Type
- Adolescence
- Adult
- Geriatric
On the basis of patient type, the North America adenomyosis drugs market is segmented into adolescence, adult, and geriatric.
Dosage Form
- Parenteral
- Oral
- Others
On the basis of dosage form, the North America adenomyosis drugs market is segmented into parenteral, oral, and others.
End User
- Hospitals
- Clinics
- Specialty center
- Home healthcare
- Ambulatory centers
- Others
On the basis of end user, the North America adenomyosis drugs market is segmented into hospitals, clinics, specialty center, home healthcare, ambulatory centers, and others.
Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
- Others
On the basis of distribution channel, the North America adenomyosis drugs market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others.
North America Adenomyosis Drugs Market Regional Analysis/Insights
North America adenomyosis drugs market is analyzed, and market size insights and trends are provided by type, treatment, patient type, dosage form, distribution channel, and end user, as referenced above.
The regions covered in the North America adenomyosis drugs market report are U.S., Canada, and Mexico in North America.
The U.S. is expected to dominate the North American adenomyosis drugs market in the forecast period due to a large number of major market players.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Adenomyosis Drugs Market Share Analysis
North America adenomyosis drugs market competitive landscape provides details of the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the North America adenomyosis drugs market.
Some of the key players in the market are Mayne Pharma Group Limited, Accord Healthcare, Tolmar Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, TerSera Therapeutics LLC, Ferring B.V., Lannett, Par Pharmaceutical (A Subsidiary of Endo International plc), Hikma Pharmaceuticals PLC, Context Therapeutics Inc., Viatris Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Zydus Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd, AbbVie Inc., Abbott, GlaxoSmithKline plc., Novartis AG, Amneal Pharmaceuticals LLC, Johnson & Johnson Services, Inc., Sanofi, Dr. Reddy's Laboratories Ltd., among others.
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, and North America Vs. Regional and Vendor Share Analysis. Please request an analyst call in case of further inquiry.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA ADENOMYOSIS DRUGS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S MODEL
4.2 PORTER
5 EPIDEMIOLOGY
6 PIPELINE ANALYSIS FOR ADENOMYOSIS DRUGS MARKET
7 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: REGULATORY SCENARIO
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 HIGH PREVALENCE OF ADENOMYOSIS DISORDERS
8.1.2 INCREASE IN RESEARCH AND DEVELOPMENT OF ADENOMYOSIS DRUG
8.1.3 ADVANCEMENT IN DIAGNOSIS OF ADENOMYOSIS
8.1.4 INCREASING AWARENESS OF ADENOMYOSIS
8.2 RESTRAINTS
8.2.1 HIGH COST OF TESTING AND MEDICATIONS
8.2.2 ADVERSE SIDE-EFFECTS OF ADENOMYOSIS DRUGS
8.3 OPPORTUNITIES
8.3.1 INCREASE DEMAND FOR DISEASE-SPECIFIC DRUG TREATMENT
8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS
8.3.3 INCREASING SUPPORT OF PRIVATE AND GOVERNMENT AGENCIES FOR TREATMENT
8.4 CHALLENGES
8.4.1 ALTERNATIVE ADENOMYOSIS THERAPIES
8.4.2 IMPROPER DIAGNOSIS OF ADENOMYOSIS
9 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY TYPE
9.1 OVERVIEW
9.2 DIFFUSE
9.2.1 BY SYMPTOMS
9.2.1.1 MENORRHAGIA
9.2.1.2 PELVIC PAIN
9.2.1.3 DYSMENORRHEA
9.2.1.4 METRORRHAGIA
9.2.1.5 OTHERS
9.2.2 BY AGE
9.2.2.1 BETWEEN 20 TO 45
9.2.2.2 ABOVE 45
9.2.2.3 BEFORE 20
9.3 NODULAR
9.3.1 BY SYMPTOMS
9.3.1.1 MENORRHAGIA
9.3.1.2 PELVIC PAIN
9.3.1.3 DYSMENORRHEA
9.3.1.4 METRORRHAGIA
9.3.1.5 OTHERS
9.3.2 BY AGE
9.3.2.1 BETWEEN 20 TO 45
9.3.2.2 ABOVE 45
9.3.2.3 BEFORE 20
9.4 SCLEROTIC
9.4.1 BY SYMPTOMS
9.4.1.1 MENORRHAGIA
9.4.1.2 PELVIC PAIN
9.4.1.3 DYSMENORRHEA
9.4.1.4 METRORRHAGIA
9.4.1.5 OTHERS
9.4.2 BY AGE
9.4.2.1 BETWEEN 20 TO 45
9.4.2.2 ABOVE 45
9.4.2.3 BEFORE 20
9.5 ADULT CYSTIC
9.5.1 BY SYMPTOMS
9.5.1.1 MENORRHAGIA
9.5.1.2 PELVIC PAIN
9.5.1.3 DYSMENORRHEA
9.5.1.4 METRORRHAGIA
9.5.1.5 OTHERS
9.5.2 BY AGE
9.5.2.1 BETWEEN 20 TO 45
9.5.2.2 ABOVE 45
9.5.2.3 BEFORE 20
9.6 OTHERS
9.6.1 ATYPICAL POLYPOID ADENOMYOMAS
9.6.1.1 BY SYMPTOMS
9.6.1.1.1 MENORRHAGIA
9.6.1.1.2 PELVIC PAIN
9.6.1.1.3 DYSMENORRHEA
9.6.1.1.4 METRORRHAGIA
9.6.1.1.5 OTHERS
9.6.1.2 BY AGE
9.6.1.2.1 BETWEEN 20 TO 45
9.6.1.2.2 ABOVE 45
9.6.1.2.3 BEFORE 20
9.6.2 JUVENILE CYSTIC ADENOMYOSIS
9.6.2.1 BY SYMPTOMS
9.6.2.1.1 MENORRHAGIA
9.6.2.1.2 PELVIC PAIN
9.6.2.1.3 DYSMENORRHEA
9.6.2.1.4 METRORRHAGIA
9.6.2.1.5 OTHERS
9.6.2.2 BY AGE
9.6.2.2.1 BETWEEN 20 TO 45
9.6.2.2.2 ABOVE 45
9.6.2.2.3 BEFORE 20
10 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 HORMONE MEDICATIONS
10.2.1 GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS)
10.2.1.1 LEUPROLIDE ACETATE
10.2.1.2 NAFARELIN
10.2.1.3 GOSERELIN
10.2.1.4 OTHERS
10.2.2 ESTROGEN-PROGESTIN
10.2.2.1 ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P)
10.2.2.2 CONJUGATED ESTROGENS (E) + MEDROXYPROGESTERONE ACETATE (P)
10.2.2.3 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P)
10.2.2.4 OTHERS
10.2.3 SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN
10.2.3.1 LEVONORGESTREL
10.2.3.2 MIFEPRISTONE
10.2.3.3 ASOPRISNIL
10.2.3.4 LONAPRISAN
10.2.3.5 TELAPRISTONE ACETATE
10.2.3.6 ULIPRISTAL ACETATE
10.2.3.7 ONAPRISTONE
10.2.4 AROMATASE INHIBITORS
10.2.4.1 ARIMIDEX
10.2.4.2 FEMARA
10.2.4.3 OTHERS
10.2.5 GONADOTROPIN-RELEASING HORMONE ANTAGONIST
10.2.5.1 ELAGOLIX
10.2.5.2 FIRMAGON
10.2.5.3 OTHERS
10.2.6 SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)
10.2.6.1 TAMOXIFEN
10.2.6.2 RALOXIFENE
10.2.6.3 BAZEDOXIFENE
10.2.6.4 CLOMIPHENE
10.2.6.5 TOREMIFENE
10.2.6.6 OSPEMIFENE
10.2.6.7 LASOFOXIFENE
10.2.7 ANDROGEN DERIVATIVES
10.2.7.1 DANAZOL
10.2.7.2 GESTRINONE
10.3 ANTI-INFLAMMATORY DRUGS
10.3.1 NON-SELECTIVE NSAIDS
10.3.1.1 IBUPROFEN
10.3.1.2 NAPROXEN
10.3.1.3 DICLOFENAC
10.3.1.4 MEFENAMIC ACID
10.3.1.5 PIROXICAM
10.3.1.6 OTHERS
10.3.2 SELECTIVE COX-2 NSAIDS
10.3.2.1 CELECOXIB
10.3.2.2 VALDECOXIB
10.3.2.3 OTHERS
10.3.3 PREFERENTIAL COX-2 INHIBITORS
10.3.3.1 MELOXICAM
10.3.3.2 ETODOLAC
10.3.3.3 OTHERS
10.4 OTHERS
11 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE
11.1 OVERVIEW
11.2 ADULT
11.3 GERIATRIC
11.4 ADOLESCENCE
12 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM
12.1 OVERVIEW
12.2 ORAL
12.2.1 TABLETS
12.2.2 CAPSULES
12.2.3 SOLUTION
12.2.4 SUSPENSION
12.3 PARENTERAL
12.3.1 INTRAVENOUS
12.3.2 INTRAMUSCULAR
12.4 OTHERS
13 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITAL
13.3 CLINICS
13.4 SPECIALTY CENTER
13.5 HOME HEALTHCARE
13.6 AMBULATORY CENTERS
13.7 OTHERS
14 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 ONLINE PHARMACY
14.5 OTHERS
15 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY REGION
15.1 NORTH AMERICA
15.1.1 U.S.
15.1.2 CANADA
15.1.3 MEXICO
16 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 ABBVIE INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.1.5.1 ACQUISITION
18.1.5.2 PARTNERSHIP
18.2 PFIZER INC.
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENT
18.2.5.1 MERGER
18.3 SANOFI
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.3.5.1 MERGER
18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.4.5.1 PARTNERSHIP
18.5 BAYER AG
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENT
18.5.5.1 ACQUISITION
18.6 ABBOTT
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENT
18.6.4.1 PRODUCT APPROVAL
18.7 ACCORD HEALTHCARE
18.7.1 COMPANY SNAPSHOT
18.7.2 PRODUCT PORTFOLIO
18.7.3 RECENT DEVELOPMENT
18.8 AMNEAL PHARMACEUTICALS LLC
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENTS
18.8.4.1 EVENT
18.9 ASTRAZENECA
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENTS
18.9.4.1 EXPANSION
18.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
18.10.1 COMPANY SNAPSHOT
18.10.2 REVENUE ANALYSIS
18.10.3 PRODUCT PORTFOLIO
18.10.4 RECENT DEVELOPMENT
18.11 CONTEXT THERAPEUTICS INC.
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENT
18.11.3.1 EVENT
18.12 DR. REDDY’S LABORATORIES LTD.
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENT
18.12.4.1 ACQUISITION
18.13 FERRING B.V.
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENTS
18.13.3.1 COLLABORATION
18.14 GLAXOSMITHKLINE PLC
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENTS
18.14.4.1 PARTNERSHIP
18.15 HIKMA PHARMACEUTICALS PLC
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENT
18.16 JOHNSON & JOHNSON SERVICES, INC.
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENT
18.16.4.1 EVENT
18.17 LANNETT
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENT
18.17.4.1 EVENT
18.18 MAYNE PHARMA GROUP LIMITED
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENT
18.18.4.1 PRODUCT LAUNCH
18.19 NOVARTIS AG
18.19.1 COMPANY SNAPSHOT
18.19.2 REVENUE ANALYSIS
18.19.3 PRODUCT PORTFOLIO
18.19.4 RECENT DEVELOPMENTS
18.19.4.1 PRODUCT DEVELOPMENT
18.19.4.2 ACQUISITION
18.2 PAR PHARMACEUTICAL ( A SUBSIDIARY OF ENDO INTERNATIONAL PLC)
18.20.1 COMPANY SNAPSHOT
18.20.2 REVENUE ANALYSIS
18.20.3 PRODUCT PORTFOLIO
18.20.4 RECENT DEVELOPMENTS
18.21 SUN PHARMACEUTICAL INDUSTRIES LTD
18.21.1 COMPANY SNAPSHOT
18.21.2 REVENUE ANALYSIS
18.21.3 PRODUCT PORTFOLIO
18.21.4 RECENT DEVELOPMENT
18.22 TERSERA THERAPEUTICS LLC
18.22.1 COMPANY SNAPSHOT
18.22.2 PRODUCT PORTFOLIO
18.22.3 RECENT DEVELOPMENT
18.22.3.1 AGREEMENT
18.23 TOLMAR PHARMACEUTICALS, INC.
18.23.1 COMPANY SNAPSHOT
18.23.2 PRODUCT PORTFOLIO
18.23.3 RECENT DEVELOPMENT
18.23.3.1 PRODUCT LAUNCH
18.23.3.2 EXPANSION
18.24 VIATRIS INC
18.24.1 COMPANY SNAPSHOT
18.24.2 REVENUE ANALYSIS
18.24.3 PRODUCT PORTFOLIO
18.24.4 RECENT DEVELOPMENT
18.24.4.1 AGREEMENT
18.25 ZYDUS PHARMACEUTICALS, INC.
18.25.1 COMPANY SNAPSHOT
18.25.2 PRODUCT PORTFOLIO
18.25.3 RECENT DEVELOPMENTS
18.25.3.1 ACQUISITION
19 QUESTIONNAIRE
20 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 2 NORTH AMERICA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 3 NORTH AMERICA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 4 NORTH AMERICA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 5 NORTH AMERICA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 6 NORTH AMERICA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 7 NORTH AMERICA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 8 NORTH AMERICA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 9 NORTH AMERICA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 10 NORTH AMERICA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 11 NORTH AMERICA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 12 NORTH AMERICA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 13 NORTH AMERICA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 14 NORTH AMERICA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 15 NORTH AMERICA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 16 NORTH AMERICA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 17 NORTH AMERICA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 18 NORTH AMERICA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 19 NORTH AMERICA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 20 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 21 NORTH AMERICA HORMONE MEDICATION IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 22 NORTH AMERICA HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 23 NORTH AMERICA GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 24 NORTH AMERICA ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 25 NORTH AMERICA SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 26 NORTH AMERICA AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 27 NORTH AMERICA GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 28 NORTH AMERICA SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 29 NORTH AMERICA ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 30 NORTH AMERICA ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 31 NORTH AMERICA ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 32 NORTH AMERICA NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 33 NORTH AMERICA SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 34 NORTH AMERICA PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 35 NORTH AMERICA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 36 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 37 NORTH AMERICA ADULT IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 38 NORTH AMERICA GERIATRIC IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 39 NORTH AMERICA ADOLESCENCE IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 40 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 41 NORTH AMERICA ORAL IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 42 NORTH AMERICA ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 43 NORTH AMERICA PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 44 NORTH AMERICA PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 45 NORTH AMERICA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 46 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 47 NORTH AMERICA HOSPITAL IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 48 NORTH AMERICA CLINICS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 49 NORTH AMERICA SPECIALTY CENTER IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 50 NORTH AMERICA HOME HEALTHCARE IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 51 NORTH AMERICA AMBULATORY CENTERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 52 NORTH AMERICA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 53 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 54 NORTH AMERICA HOSPITAL PHARMACY IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 55 NORTH AMERICA RETAIL PHARMACY IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 56 NORTH AMERICA ONLINE PHARMACY IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 57 NORTH AMERICA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 58 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)
TABLE 59 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 60 NORTH AMERICA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 61 NORTH AMERICA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 62 NORTH AMERICA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 63 NORTH AMERICA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 64 NORTH AMERICA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 65 NORTH AMERICA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 66 NORTH AMERICA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 67 NORTH AMERICA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 68 NORTH AMERICA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 69 NORTH AMERICA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 70 NORTH AMERICA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 71 NORTH AMERICA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 72 NORTH AMERICA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 73 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 74 NORTH AMERICA HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 75 NORTH AMERICA GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 76 NORTH AMERICA ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 77 NORTH AMERICA SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 78 NORTH AMERICA AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 79 NORTH AMERICA GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 80 NORTH AMERICA SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 81 NORTH AMERICA ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 82 NORTH AMERICA ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 83 NORTH AMERICA NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 84 NORTH AMERICA SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 85 NORTH AMERICA PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 86 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 87 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 88 NORTH AMERICA ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 89 NORTH AMERICA PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 90 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 91 NORTH AMERICA ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 92 U.S. ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 93 U.S. DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 94 U.S. DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 95 U.S. NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 96 U.S. NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 97 U.S. SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 98 U.S. SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 99 U.S. ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 100 U.S. ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 101 U.S. OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 102 U.S. ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 103 U.S. ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 104 U.S. JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 105 U.S. JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 106 U.S. ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 107 U.S. HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 108 U.S. GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 109 U.S. ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 110 U.S. SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 111 U.S. AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 112 U.S. GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 113 U.S. SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 114 U.S. ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 115 U.S. ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 116 U.S. NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 117 U.S. SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 118 U.S. PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 119 U.S. ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 120 U.S. ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 121 U.S. ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 122 U.S. PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 123 U.S. ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 124 U.S. ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 125 CANADA ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 126 CANADA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 127 CANADA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 128 CANADA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 129 CANADA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 130 CANADA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 131 CANADA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 132 CANADA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 133 CANADA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 134 CANADA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 135 CANADA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 136 CANADA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 137 CANADA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 138 CANADA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 139 CANADA ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 140 CANADA HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 141 CANADA GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 142 CANADA ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 143 CANADA SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 144 CANADA AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 145 CANADA GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 146 CANADA SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 147 CANADA ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 148 CANADA ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 149 CANADA NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 150 CANADA SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 151 CANADA PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 152 CANADA ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 153 CANADA ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 154 CANADA ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 155 CANADA PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 156 CANADA ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 157 CANADA ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 158 MEXICO ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 159 MEXICO DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 160 MEXICO DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 161 MEXICO NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 162 MEXICO NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 163 MEXICO SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 164 MEXICO SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 165 MEXICO ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 166 MEXICO ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 167 MEXICO OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 168 MEXICO ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 169 MEXICO ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 170 MEXICO JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)
TABLE 171 MEXICO JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 172 MEXICO ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 173 MEXICO HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 174 MEXICO GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 175 MEXICO ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 176 MEXICO SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 177 MEXICO AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 178 MEXICO GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 179 MEXICO SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 180 MEXICO ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 181 MEXICO ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 182 MEXICO NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 183 MEXICO SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 184 MEXICO PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 185 MEXICO ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 186 MEXICO ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 187 MEXICO ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 188 MEXICO PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 189 MEXICO ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 190 MEXICO ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
List of Figure
FIGURE 1 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: END USER COVERAGE GRID
FIGURE 10 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS GROWING AT THE FASTEST PACE IN NORTH AMERICA ADENOMYOSIS DRUGS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 HIGH PREVALENCE OF ADENOMYOSIS DISORDER AND INCREASE THE RESEARCH AND DEVELOPMENT OF ADENOMYOSIS DRUG ARE DRIVING THE NORTH AMERICA ADENOMYOSIS DRUGS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DIFFUSE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA ADENOMYOSIS DRUGS MARKET IN 2022 & 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA ADENOMYOSIS DRUGS MARKET
FIGURE 16 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY TYPE, 2021
FIGURE 17 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY TYPE, 2022-2029 (USD THOUSAND)
FIGURE 18 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY TREATMENT, 2021
FIGURE 21 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY TREATMENT, 2022-2029 (USD THOUSAND)
FIGURE 22 NORTH AMERICA ADENOMYOSIS DRUGS: BY TREATMENT, CAGR (2022-2029)
FIGURE 23 NORTH AMERICA ADENOMYOSIS DRUGS: BY TREATMENT, LIFELINE CURVE
FIGURE 24 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY PATIENT TYPE, 2021
FIGURE 25 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY PATIENT TYPE, 2022-2029 (USD THOUSAND)
FIGURE 26 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY PATIENT TYPE, CAGR (2022-2029)
FIGURE 27 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 28 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY DOSAGE FORM, 2021
FIGURE 29 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY DOSAGE FORM, 2022-2029 (USD THOUSAND)
FIGURE 30 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY DOSAGE FORM, CAGR (2022-2029)
FIGURE 31 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 32 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY END USER, 2021
FIGURE 33 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY END USER, 2022-2029 (USD THOUSAND)
FIGURE 34 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 35 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 36 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 37 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD THOUSAND)
FIGURE 38 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 39 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 40 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: SNAPSHOT (2021)
FIGURE 41 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY COUNTRY (2021)
FIGURE 42 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 43 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 44 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: BY TYPE (2022-2029)
FIGURE 45 NORTH AMERICA ADENOMYOSIS DRUGS MARKET: COMPANY SHARE 2021 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
